{"name":"Candel Therapeutics","slug":"candel-therapeutics","ticker":"CADL","exchange":"NASDAQ","domain":"candeltherapeutics.com","description":"","hq":"Needham, MA","founded":0,"employees":"","ceo":"","sector":"Oncology / Viral Immunotherapy","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":125000,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":4,"colorKey":"oncology","drugs":[{"name":"AdV-tk","genericName":"AdV-tk","slug":"adv-tk","indication":"Metastatic pancreatic cancer","status":"phase_3"},{"name":"CAN-2409","genericName":"CAN-2409","slug":"can-2409","indication":"Metastatic solid tumors","status":"phase_2"},{"name":"Placebo + valacyclovir","genericName":"Placebo + valacyclovir","slug":"placebo-valacyclovir","indication":"Likely oncolytic virus-based immunotherapy in combination with valacyclovir (specific indication unknown without trial details)","status":"phase_3"},{"name":"aglatimagene besadenovec + valacyclovir","genericName":"aglatimagene besadenovec + valacyclovir","slug":"aglatimagene-besadenovec-valacyclovir","indication":"Metastatic pancreatic cancer","status":"phase_3"}]}],"pipeline":[{"name":"AdV-tk","genericName":"AdV-tk","slug":"adv-tk","phase":"phase_3","mechanism":"AdV-tk is an oncolytic adenovirus expressing herpes simplex virus thymidine kinase that replicates in tumor cells and sensitizes them to ganciclovir, triggering both direct viral lysis and immune activation.","indications":["Metastatic pancreatic cancer","Ovarian cancer"],"catalyst":""},{"name":"CAN-2409","genericName":"CAN-2409","slug":"can-2409","phase":"phase_2","mechanism":"CAN-2409 is a T-cell engager that targets the CD3 component of the T-cell receptor.","indications":["Metastatic solid tumors"],"catalyst":""},{"name":"Placebo + valacyclovir","genericName":"Placebo + valacyclovir","slug":"placebo-valacyclovir","phase":"phase_3","mechanism":"Valacyclovir is an antiviral prodrug that inhibits herpes simplex virus DNA polymerase, while the placebo control allows assessment of the combination's efficacy in a phase 3 trial.","indications":["Likely oncolytic virus-based immunotherapy in combination with valacyclovir (specific indication unknown without trial details)"],"catalyst":""},{"name":"aglatimagene besadenovec + valacyclovir","genericName":"aglatimagene besadenovec + valacyclovir","slug":"aglatimagene-besadenovec-valacyclovir","phase":"phase_3","mechanism":"Aglatimagene besadenovec is an oncolytic adenovirus expressing IL-12 that replicates in tumor cells and triggers immune activation, combined with valacyclovir (an antiviral) to modulate viral replication kinetics.","indications":["Metastatic pancreatic cancer","Ovarian cancer"],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":4,"phaseCounts":{"phase_3":3,"phase_2":1},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}